Labcorp stock edges higher after MLM Medical Labs acquisition highlights growth push

Published on 09/15/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock recently traded near USD 311 on the NYSE as of September 11, 2026, staying within its 52-week range after beating earnings and reaffirming 2026 EPS guidance. The company’s acquisition of MLM Medical Labs underscores its focus on expanding central lab services for clinical trials.

Modernes Diagnostiklabor mit Technikern in weißen Kitteln an automatisierten Analysegeräten — Labcorp (ISIN US50540R4092) betreibt moderne klinische Labore mit Technikern und automatisierten Diagnosegeräten hinter Glasfassaden, Illustration mit AI erstellt.

Labcorp Holdings Inc. stock (ISIN US50540R4092) most recently closed around USD 311 per share on the New York Stock Exchange on September 11, 2026, leaving the shares within their prevailing 52-week corridor and stabilizing after earlier volatility in the name.

MLM Medical Labs deal strengthens Labcorp’s trial services

The latest strategic catalyst for Labcorp stock is the company’s purchase of MLM Medical Labs, a global central and specialty laboratory provider serving clinical trials and biopharmaceutical customers, as reported on September 15, 2026 by Pulse 2.0.

According to Pulse 2.0 on September 15, 2026, private equity firm Great Point Partners completed the sale of its portfolio company MLM Medical Labs to Labcorp, marking an exit from an asset positioned in the fast-growing central and specialty lab segment for clinical trials.

Earnings beat and guidance underpin valuation

Recent trading in Labcorp stock has been shaped by the company’s latest quarterly results, where it beat earnings expectations and reaffirmed full-year guidance for 2026, as highlighted in a corporate-news overview by Ad-hoc-news on September 14, 2026.

The same overview notes that Labcorp reaffirmed its adjusted EPS guidance range of USD 18.10 to USD 18.55 for the 2026 financial year, providing investors with a clearly quantified corridor for expected earnings this year according to Ad-hoc-news.

In the same report, Labcorp is described as having recently beaten quarterly earnings estimates, which, combined with the guidance reaffirmation, supports confidence in management’s outlook and the sustainability of the adjusted EPS range for fiscal year 2026 per Ad-hoc-news.

Stock holds near USD 311 after recent swing

Per the same corporate-news coverage, Labcorp stock closed at about USD 311 on the New York Stock Exchange on September 11, 2026 after a recent single-digit percent move against the prior session’s close, indicating a moderate reaction rather than a sharp swing in the shares according to Ad-hoc-news.

Earlier sessions saw the stock decline by roughly 4.3 percent before finding support near the current USD 311 region, so the latest close now stands above that recent low while still below the highs reached earlier in the 52-week period, as described in the same overview from Ad-hoc-news.

Closing price and investor takeaway

For investors, the combination of a completed acquisition in the central lab space and an earnings beat with reaffirmed 2026 EPS guidance provides a dual narrative: operational expansion through the MLM Medical Labs deal and a quantified earnings framework that currently supports Labcorp stock around USD 311 on the NYSE as of September 11, 2026.